|
Abingworth believes scientific excellence is worth investing in. The company is a venture capital firm focused on all stages of life science investments and health care businesses in Europe and the US. It typically invests from $20 million to $80 million over the life of its involvement, a span of time averaging three to eight years. Portfolio holdings include drug developers Avila Therapeutics and Dicerna Pharmaceuticals and orthopedic products maker Stanmore Implants. The company has invested in companies engaged in structural biology, neuroscience, cell biology, gene therapy, and health care services. Abingworth has about $1.25 billion under management; it has established seven funds since 1973.
|
| | | Contact Information | |
Address: |
38 Jermyn St.
London SW1Y 6DN, United Kingdom
| | Phone: | +44-207-534-1500 | | Fax: | +44-207-287-0480 |
|
| Financial
Highlights | | Fiscal Year End: | June | | Revenue (2008): | 22.60 M | | Employees (2008): | 10 |
|
|
Key People
| | • |
President, Abingworth Management, Inc.:
Jonathan J. MacQuitty
| | • |
Managing Director:
Stephen Bunting
| | • |
CFO and Director, UK:
James Abell
|
|
|
